Literature DB >> 16098841

Rationale for new American Diabetes Association Guidelines: are national cholesterol education program goals adequate for the patient with diabetes mellitus?

Steven Haffner1.   

Abstract

Both the American Diabetes Association (ADA) and the National Cholesterol Education Program (NCEP) consider type 2 diabetes mellitus to be a coronary artery disease (CAD) risk equivalent and thus suggest that patients with either diabetes or CAD should have their plasma levels of low-density lipoprotein (LDL) cholesterol lowered to <2.59 mmol/L (<100 mg/dL). Recently the NCEP issued a white paper suggesting an even lower plasma LDL cholesterol goal of <1.81 mmol/L (<70 mg/dL) for patients at high cardiovascular risk, including patients with diabetes. This rationale was based partly on the higher risk of future cardiovascular disease seen in patients who have diabetes with or without preexisting cardiovascular disease than in nondiabetic subjects with preexisting cardiovascular disease. Additionally, as reported in the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE-IT) study, high-dose lipid-lowering therapy has been shown to further reduce CAD event rates compared with conventional therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16098841     DOI: 10.1016/j.amjcard.2005.05.012

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Mobile health (mHealth) based medication adherence measurement - a pilot trial using electronic blisters in diabetes patients.

Authors:  Helmut Brath; Jürgen Morak; Thomas Kästenbauer; Robert Modre-Osprian; Hermine Strohner-Kästenbauer; Mark Schwarz; Willem Kort; Günter Schreier
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

2.  Tocotrienol rich fraction supplementation improved lipid profile and oxidative status in healthy older adults: A randomized controlled study.

Authors:  Siok-Fong Chin; Johari Ibahim; Suzana Makpol; Noor Aini Abdul Hamid; Azian Abdul Latiff; Zaiton Zakaria; Musalmah Mazlan; Yasmin Anum Mohd Yusof; Aminuddin Abdul Karim; Wan Zurinah Wan Ngah
Journal:  Nutr Metab (Lond)       Date:  2011-06-24       Impact factor: 4.169

3.  Baseline serum cholesterol is associated with a response to pegylated interferon alfa-2b and ribavirin therapy for chronic hepatitis C genotype 2.

Authors:  Naota Taura; Tatsuki Ichikawa; Hisamitsu Miyaaki; Yoshiko Kadokawa; Takuya Tsutsumi; Shotaro Tsuruta; Yuji Kato; Osami Inoue; Noboru Kinoshita; Kazuo Ohba; Hiroyuki Kato; Kazuyuki Ohata; Junichi Masuda; Keisuke Hamasaki; Hiroshi Yatsuhashi; Kazuhiko Nakao
Journal:  Gastroenterol Res Pract       Date:  2012-11-05       Impact factor: 2.260

4.  Changes in risk variables of metabolic syndrome since childhood in pre-diabetic and type 2 diabetic subjects: the Bogalusa Heart Study.

Authors:  Quoc Manh Nguyen; Sathanur R Srinivasan; Ji-Hua Xu; Wei Chen; Gerald S Berenson
Journal:  Diabetes Care       Date:  2008-07-15       Impact factor: 17.152

5.  Application of the modified Framingham cardiovascular risk score to newly diagnosed type 2 black African diabetic patients.

Authors:  Andre Pascal Kengne; Mesmin Dehayem; Simeon Pierre Choukem; Paschal Awah; Jean-Claude Mbanya
Journal:  Cardiovasc J Afr       Date:  2007 Jul-Aug       Impact factor: 1.167

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.